2014
DOI: 10.1073/pnas.1316312111
|View full text |Cite
|
Sign up to set email alerts
|

TRAIL-coated leukocytes that kill cancer cells in the circulation

Abstract: Metastasis through the bloodstream contributes to poor prognosis in many types of cancer. Mounting evidence implicates selectinbased adhesive interactions between cancer cells and the blood vessel wall as facilitating this process, in a manner similar to leukocyte trafficking during inflammation. Here, we describe a unique approach to target and kill colon and prostate cancer cells in the blood that causes circulating leukocytes to present the cancer-specific TNF-related apoptosis inducing ligand (TRAIL) on th… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

11
203
0

Year Published

2015
2015
2021
2021

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 188 publications
(214 citation statements)
references
References 47 publications
11
203
0
Order By: Relevance
“…Such functionalized oil surface could create a high local concentration of the ligands and lead to more efficient interactions with the receptors on the cell surface (Fig. 3D) (26), similar to the high apoptosis rate induced by TRAIL-coated leukocytes in the work by Mitchell et al (27).…”
Section: Resultssupporting
confidence: 55%
“…Such functionalized oil surface could create a high local concentration of the ligands and lead to more efficient interactions with the receptors on the cell surface (Fig. 3D) (26), similar to the high apoptosis rate induced by TRAIL-coated leukocytes in the work by Mitchell et al (27).…”
Section: Resultssupporting
confidence: 55%
“…Second, to overcome the ethical concerns and cell scarcity limitations associated with NSCs (6, 7), here we have demonstrated the efficacy of adipose-derived stem cells as an abundant and easily accessible autologous cell source for targeting infiltrating GBM and microsatellites over long distances in vivo. Third, membrane-bound TRAIL was chosen as a therapeutic agent overexpressed by polymeric nanoparticles, which markedly augment receptor clustering and apoptosis stimulation in cancer cells (30,31). Last, patient-derived GBM xenograft cells were used rather than immortalized cell lines, which have been shown to better at preserving tumor phenotype and predicting clinically relevant outcomes (26).…”
Section: Discussionmentioning
confidence: 99%
“…Potential reasons for the lack of clinical efficacy may include insufficient tumor exposure (16,17) and/or weak engagement of the extrinsic pathway (10,13). We have chosen membrane display of TRAIL, which could more faithfully mimic the endogenous ligand, and markedly augment receptor clustering and apoptosis stimulation in cancer cells (30,31). Indeed, our results showed polymeric nanoparticles-induced TRAIL overexpressing led to effective targeting of intracranial brain tumor and microsatellite tumor cells in a patientderived glioblastoma orthotopic xenograft models, paving the way for clinical translation of this innovative therapeutic approach.…”
Section: Discussionmentioning
confidence: 99%
“…þ cells have been recently tested in preclinical setting to deliver TRAIL, with the aim of optimizing bioavailability and stability of this molecule (10)(11)(12)(13)(14)(15). An innovate option to deliver TRAIL could be to embed it within vesicular structures directly generated by TRAIL-expressing cells.…”
Section: Introductionmentioning
confidence: 99%